Optimal therapy and management of endometrial cancer

References

• Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancerj Clin. 52,23–47 (2002).
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Blausteids Pathology of the Female Genital Tract (4th Kurman RJ (Ed.). Springer-Verlag. New York, NY, USA, 439–486 (1994).
   Google Scholar
• Platz CE, Benda JA. Female genital tract cancer. Cancer75(1 Suppl.), 270–294 (1995).
   Google Scholar
• Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet. Gynecol 64(3), 417–420 (1984).
   Google Scholar
• Whitaker GK, Lee RB, Benson WL. Carcinoma of the endometrium in young women. 11/Pl. Med. 151(1), 25–31 (1986).
   Google Scholar
• Hill HA, Coates RJ, Austin H et al Racial differences in tumor grade among women with endometrial cancer. Gynecol 56(2), 154–163 (1995).
   Google Scholar
• Connell PP, Rotmensch J, Waggoner SE, Mundt AJ. Race and clinical outcome inendometrial carcinoma. Obstet. Gynecol 94(5 Pt 1), 713–720 (1999).
   Google Scholar
• Barakat RR, Grigsby PVV, Sabbatini P, Zaino RJ. Corpus: epithelial tumors. In: Principles and Practice of Gynecologic Oncology (3rd Frlition). Hoskins WI Perez CA, Young RC (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 924 (2000).
   Google Scholar
• Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving anti-estrogens. Cancer Treat. Rep. 69(2), 237–238 (1987).
   Google Scholar
• Fomander T, Rutqvist LE, Cedermark B et al. Adjuvant tamoxifen in early breast cancer:occurrence of new primary cancers. Lancet 1(8630), 117–120 (1989).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Natl Cancer Inst. 90(18), 1371–1388 (1998).
   Google Scholar
• Vasen HF, Wijnen JT, Menko FH et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110(4), 1020–1027 (1996).
   PubMed Web of Science ®Google Scholar
• Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Lit. J. Cancer 81 (2), 214–218 (1999).
   Google Scholar
• Dunlop MG, Farrington SM, Carothers AD et al Cancer risk associated with germline DNA mismatch repair gene mutations. Hum. Md. Genet. 6(1), 105–110 (1997).
   Google Scholar
• Hawwa ZM, Nahhas WA, Copenhaver EH. Postmenopausal bleeding. Lahey Clin. Found. Bull. 19(2), 61–70 (1970).
   Google Scholar
• Dijkhuizen FP, Md. BVV, Brolmann HA, Heintz AR The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 89(8), 1765–1772 (2000).
   PubMed Web of Science ®Google Scholar
• Karlsson B, Granberg S, Wikland M et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding — a Nordic multicenter study. Am. J. Obstet. Gynecol 172(5), 1488–1494 (1995).
   Google Scholar
• Goldstein RB, Bite PL, Benson CB et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. J. Ultrasound Med 20(10), 1025–1036 (2001).
   PubMed Web of Science ®Google Scholar
• Lahti E, Blanco G, Kauppila A, Apaja- Sarkkinen M, Taskinen PJ, Laatikainen T Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81(5), 660–664 (1993).
   PubMedGoogle Scholar
• Cheng WF, Lin HH, Torng PL, Huang Sc. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 66(2), 233–237 (1997).
   PubMed Web of Science ®Google Scholar
• Kedar RP, Bourne TH, Powles TJ et al Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 28, 343(8909), 1318–1321 (1994).
   Google Scholar
• Cohen I, Rosen DJ, Shapira J et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52(2), 185–190 (1994).
   PubMed Web of Science ®Google Scholar
• Ascher SM, Imaoka I, Lage JM. Tamoxifen- induced uterine abnormalities: the role of imaging. Radiology 214(1), 29–38 (2000).
   PubMed Web of Science ®Google Scholar
• Levine D, Gosink BB, Johnson LA. Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy. Radiology197 (3), 603–608 (1995).
   PubMed Web of Science ®Google Scholar
• Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 90(3), 441–447 (1997).
   Google Scholar
• Creasman WT Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer60 (8 Suppl.), 2035-2041 (1987).
   Google Scholar
• ••Defined the pathological risk factors fortumor spread.
   Google Scholar
• Hatch K. Endometrial cancer: what is the proper extent of surgical staging?Proc. 25th Ann. Con( Soc. Gynecol Oncol (1994).
   Google Scholar
• Vorgias G, Hintipas E, Katsoulis M, Kalinoglou N, Dertimas B, Alcrivos T Intraoperative gross examination of myometrial invasion and cervical infiltration in patients with endometrial cancer: decision-making accuracy. Gynecol Oncol. 85(3), 483–486 (2002).
   Google Scholar
• Arango HA, Hoffman MS, Roberts WS, DeCesare SL, Fiorica JV, Drake J. Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies. Obstet Gynecol 95(4), 553–556 (2000).
   PubMed Web of Science ®Google Scholar
• Eltabbakh GH. Intraoperative clinical evaluation of lymph nodes in women with gynecologic cancer. Am. J. Obstet Gynecol. 184(6), 1177–1181 (2001).
   Google Scholar
• Girardi F, Petru E, Heydarfadai M, Haas J, Winter R. Pelvic lymphadenectomy in the surgical treatment of endometrial cancer. Gynecol arca 49(2), 177–180 (1993).
   PubMed Web of Science ®Google Scholar
• Kilgore LC, Partridge EE, Alvarez RD et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol. 56(1), 29–33 (1995).
   Google Scholar
• Yabushita H, Shimazu M, Yamada H et al. Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol Oncol. 80(2), 139–144 (2001).
   Google Scholar
• Cirisano FD Jr, Robboy SJ, Dodge RK et al. The outcome of Stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol arca 77(1), 55–65 (2000).
   PubMed Web of Science ®Google Scholar
• Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol. 74(3), 465–467 (1999).
   Google Scholar
• Partridge EE, Jessup JM, Donaldson ES et al. 1996 Patient Care Evaluation Study (PCE) of cancer of the corpus uteri. National Cancer Database (NCDB), American College of Surgery. Gynecol arca 72(3), 445 (1999).
   Google Scholar
• Society of Gynecologic Oncologists. Referral Guidelines in Gynecologic Oncology. Gynecol Oncol 78, S1-13 (2000).
   Google Scholar
• Chan JK, Lin YG, Monk BJ, Tewari K, Bloss JD, Berman ML. Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol. 97(5 Pt 1), 707–711 (2001).
   Google Scholar
• Childers JM, Brzechffa PR, Hatch KD, Surwit EA. Laparoscopically assisted surgical staging (LASS) of endometrial cancer. Gynecol Oncol. 51(1), 33–38 (1993).
   Google Scholar
• Gemignani ML, Curtin JP, Zelmanovich J, Patel DA, Venkatraman E, Barakat RR. Laparoscopic-assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges. Gynecol arca 73(1), 5–11 (1999).
   PubMed Web of Science ®Google Scholar
• Spirtos NM, Schlaerth JB, Gross GM, Spirtos TW, Schlaerth AC, Ballon SC. Cost and quality-of-life analyses of surgery for early endometrial cancer: laparotomy versus laparoscopy. Am. J. Obstet Gynecol 174(6), 1795–1799, discussion 1799–1800 (1996).
   Google Scholar
• Eltabbakh GH, Shamonki MI, Moody JM, Garafano LL. Laparoscopy as the primary modality for the treatment of women with endometrial carcinoma. Cancer91 (2), 378–387 (2001).
   PubMed Web of Science ®Google Scholar
• Boike G, Lurain J, Burke J. A comparison of laparoscopic management of endometrial cancer with traditional laparotomy. Gynecol Oncol 52,105 (1994).
   Google Scholar
• Straughn JM Jr, Huh WK, Kelly FJ et al. Conservative management of Stage I endometrial carcinoma after surgical staging. Gynecol. Oncol 84(2), 194–200 (2002).
   PubMed Web of Science ®Google Scholar
• •Large series illustrating that conservative management can be effective.
   Google Scholar
• Roberts JA, Brunetto VL, Keys HM et al. A Phase III randomized study of surgery vs. surgery plus adjuvant radiation therapy in intermediate risk endometrial carcinoma (GOG 99). Proc. Soc. Gynecol arca Ann. Meet. 70 (1998).
   Google Scholar
• Fanning J. Treatment for early endometrial cancer. Cost-effectiveness analysis. J. Reprod. Med. 44(8), 719–723 (1999).
   Google Scholar
• Barnes MN, Roland PY, Straughn M, Kilgore LC, Alvarez RD, Partridge EE. A comparison of treatment strategies for endometrial adenocarcinoma: analysis of fmancial impact. Gynecol Oncol 74(3), 443–447 (1999).
   PubMed Web of Science ®Google Scholar
• Gretz HF 3rd, Economos K, Husain A et al The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with Stage I endometrial carcinoma. Gynecol arca 61(3), 409–415 (1996).
   Google Scholar
• Naumann RW, Higgins RV, Hall JB. The use of adjuvant radiation therapy by members of the Society of Gynecologic Oncologists. Gynecol. Oncol 75(1), 4–9 (1999).
   Google Scholar
• Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in Stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56(4), 419–427 (1980).
   Google Scholar
• Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with Stage-1 endometrial
   Google Scholar
• •• carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 22,355 (9213), 1404–1411 (2000).
   Google Scholar
• Preyer 0, Obermair A, Formann E et at The impact of positive peritoneal washings and serosal and adnexal involvement on survival in patients with Stage IIIA uterine cancer. Cynecol awl. 86(3), 269–273 (2002).
   Google Scholar
• Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Cynecol awl. 46(2), 145–149 (1992).
   PubMed Web of Science ®Google Scholar
• Hirai Y, Takeshima N, Kato T, Hasumi K. Malignant potential of positive peritoneal cytology in endometrial cancer. Obstet. Cynecol 97(5 Pt 1), 725–728 (2001).
   Google Scholar
• Piver MS, Recio FO, Baker TR, Hempling RE. A prospective trial of progesterone therapy for malignant peritoneal cytology in patients with endometrial carcinoma. Cynecol awl. 47,373–376 (1992).
   PubMed Web of Science ®Google Scholar
• Vergote I, Kjorstad K, Abeler V, Kolstad A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 64(5), 1011–1016 (1989).
   PubMed Web of Science ®Google Scholar
• Morrow CP, Bundy BN, Kurman RJ et al. Relationship between surgical-pathological risk factors and outcome in clinical Stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Cynecol Oncol. 40(1), 55–65 (1991). Demonstrats the outcome of associated pathologic risk-factors.
   Google Scholar
• Goff BA, Goodman A, Muntz HG, Fuller AF Jr, Nikrui N, Rice LW Surgical Stage IV endometrial carcinoma: a study of 47 cases. Cynecol Oncol 52(2), 237–240 (1994).
   Google Scholar
• Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Cynecol Oncol 78(2), 85–91 (2000)
   PubMed Web of Science ®Google Scholar
• Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Cynecol 0401 67(1), 56–60 (1997).
   Google Scholar
• Smith RS, Kapp DS, Chen Q, Teng NN. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Lit. J. Racliat. Oncol. Biol. Phys. 48(3), 767–778 (2000).
   Google Scholar
• Kupelian PA, Eifel PJ, Tomos C, Burke TW, Delclos L, Oswald MJ. Treatment of endometrial carcinoma with radiation therapy alone. Lit. J. Racliat. Oncol Biol. Phys. 27(4), 817–824 (1993).
   Google Scholar
• Rose PG, Baker S, Kern M et al. Primary radiation therapy for endometrial carcinoma: a case controlled study. Lit. J. Racliat. Oncol Biol Phys. 27(3), 585–590 (1993).
   Google Scholar
• Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet. Cynecol 90(3), 434–440 (1997).
   Google Scholar
• Kaku T, Yoshikawa H, Tsuda H et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 167(1), 39–48 (2001).
   Google Scholar
• Aalders JG, Abeler V, Kolstad P Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Cynecol Oncol 17(1), 85–103 (1984).
   Google Scholar
• Kuten A, Grigsby PW, Perez CA, Fineberg B, Garcia DM, Simpson JR Results of radiotherapy in recurrent endometrial carcinoma: a retrospective analysis of 51 patients. Int. J. Racliat. Oncol. Biol. Phys. 17(1), 29–34 (1989).
   Google Scholar
• Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Cynecol Oncol 60(2), 288–291 (1996).
   PubMed Web of Science ®Google Scholar
• Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Cynecol awl. 75(1), 99–102 (1999).
   PubMed Web of Science ®Google Scholar
• Gemignani ML, Alektiar KM, Leitao M et al. Radical surgical resection and high-dose intraoperative radiation therapy (HDR—IORT) in patients with recurrent gynecologic cancers. Lit. J. Racliat. Oncol Biol. Phys 50(3), 687–694 (2001).
   Google Scholar
• Thigpen JT, Brady ME, Alvarez RD et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J. Gin. Oncol 17(6), 1736–1744 (1999).
   Google Scholar
• Thigpen T, Brady ME, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Gin. Oncol. 19(2), 364–367 (2001).
   Google Scholar
• Pandya KJ, Yeap BY, Weiner LM et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Co-operative Oncology Group study (E4882). ATM Clin. Oncol 24(1), 43–46 (2001).
   Google Scholar
• Fiorica J, Brunetto V, Hanjani P, Lentz S, Mannel R, Anderson W A Phase II study (GOG 153) of recurrent and advanced endometrial carcinoma treated with alternating courses of megestrol acetate and tamoxifen citrate. Proc. Am. Soc. Clin. Oncol. 19,379a (2000).
   Google Scholar
• Thigpen T, Blessing J, Homesley H, Malfetano J, DiSaia P, Yordan E. Phase DI trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Ph. Am. Soc. Qin. Oncol 12,261 (1993).
   Google Scholar
• Fleming G, Brunetto V, Bentley R et al. Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus paclitaxel (TAX) plus granulocyte colony-stimulating factor (G-CSF) in patients with advanced or recurrent endometrial cancer: a report on Gynecologic Oncology Group (GOG) protocol. Proc. Am Soc. Clin. Oncol. (2000) (Abstract 1498).
   Google Scholar
• Dimopoulos MA, Papadimitriou CA, Georgoulias V et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a Phase II multicenter study. Cynecol Oncol 78(1), 52–57 (2000).
   PubMed Web of Science ®Google Scholar
• Fleming GF, Brunetto VL, Mundt AJ, Burks RT, Look KY, Reid G. Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus CIS plus paclitaxel (TAX) in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Roc Am Soc Clin. Oncol (2002) (Abstract 807).
   Google Scholar